Health, and Interprofessional Team Monitoring After the procedure, the patient should be transferred to the intensive care unit for further monitoring up to 4 to 7 days before discharge. The transvenous pacemaker should be left for 2 to 3 days. Patients should be monitored for the following signs. 1. Any access site complications like groin hematoma and retroperitoneal hematoma 1. Arrhythmias or heart blocks 1. Hemodynamic instability 1. Stroke/transient ischemic attack 1. Contrast nephropathy 1. Myocardial ischemia TTE should be done to assess LVOT gradient and mitral regurgitation before discharge. Patients should be followed up in the clinic and checked for any signs of access site complications like arteriovenous fistula, femoral artery pseudoaneurysm, hematoma, or infection. Appropriate, timely follow-ups should be arranged along with repeat ECHO within 3 to 6 months after the procedure to assess LVOT gradients.[11] ## Review Questions - [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=128201&utm_source=pubmed&utm_campaign=reviews&utm_content=128201) - [Click here for a simplified version.](https://mdsearchlight.com/interventional-cardiology/catheter-management-of-hypertrophic-cardiomyopathy-cardiac-catheterization/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=128201) - [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/128201/?utm_source=pubmed&utm_campaign=comments&utm_content=128201) ## References 1. Authors/Task Force members. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14;35(39):2733-79. \[[PubMed: 25173338](https://pubmed.ncbi.nlm.nih.gov/25173338)\] 2. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020 Dec 22;142(25):e558-e631. \[[PubMed: 33215931](https://pubmed.ncbi.nlm.nih.gov/33215931)\] 3. Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, Ralph-Edwards A, Rakowski H, Sherrid MV, Swistel DG, Balaram S, Rastegar H, Rowin EJ, Smedira NG, Lytle BW, Desai MY, Lever HM. Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. J Am Coll Cardiol. 2015 Sep 15;66(11):1307-1308. \[[PubMed: 26361164](https://pubmed.ncbi.nlm.nih.gov/26361164)\] 4. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, Goldschlager NF, Hamilton RM,